Total Body Irradiation, Busulfan, Fludarabine Conditioning for Pediatric Acute Myeloid Leukemia Patients Treated with Hematopoietic Stem Cell Transplantation in Second Complete Remission [0.03%]
全身照射、白消安及氟达拉滨方案在儿童急性髓系白血病第二次完全缓解期患者的造血干细胞移植治疗中的应用
Jae Wook Lee,Suejung Jo,Jae Won Yoo et al.
Jae Wook Lee et al.
Purpose: The optimum conditioning regimen for pediatric acute myeloid leukemia (AML) patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) in second complete remission (CR) remains unclear. In thi...
Yiheng Yu,Daxiong Zeng
Yiheng Yu
Gaps between Supportive Care Needs and Services in Korea: Experiences and Preferences of Patients with Advanced Cancer and Their Caregivers in the Hospital and at Home [0.03%]
韩国缓和医疗需求与服务的缺口：医院及家庭终末期癌患及其照顾者体验和支持偏好调查
Min Seol Jang,In Gyu Hwang,Shin Hye Yoo et al.
Min Seol Jang et al.
Purpose: With longer survivals in advanced cancer, the need for supportive care is increasing. However, in Korea, these services remain limited, and many patients rely on long-term care hospitals. We investigated the supp...
Risk Prediction Based on Clinicopathologic Features in Korean Melanoma Patients by Machine Learning [0.03%]
基于临床病理特征的韩国黑色素瘤患者风险预测的机器学习方法
Taeho Yuh,Hyunwook Kim,Eun Sil Baek et al.
Taeho Yuh et al.
Purpose: The prognosis of malignant melanoma differs across ethnic groups, partly due to variations in histologic subtypes. Accurate risk stratification at diagnosis is crucial but remains challenging in Korea due to its ...
Impact of Carboplatin-Free Interval on Hypersensitivity Risks in Solid Tumor Patients with Silent Sensitization [0.03%]
无卡铂间期对隐形致敏实体瘤患者过敏反应的影响风险
Junyeong Jang,Jeong-Min Lee,Su Jeong Song et al.
Junyeong Jang et al.
Purpose: Carboplatin hypersensitivity reactions (HSRs) often occur after silent sensitization in patients with solid tumors through repeated uneventful exposures. The carboplatin-free interval (CFI) has been implicated in...
Genetic Variant at 6p21.1 Impairs APOBEC2 in Hypoxic Mitophagy via HIF-1α/BNIP3 in Gastric Cancer [0.03%]
胃癌中6p21.1位点的基因变异通过HIF-1α/BINP3抑制APOBEC2在缺氧介导的线粒体自噬中的作用
Zhonghua Zheng,Qian Li,Yuanliang Gu et al.
Zhonghua Zheng et al.
Purpose: Genome-wide association studies (GWASs) have identified single-nucleotide polymorphisms (SNPs) at the 6p21.1 locus associated with gastric cancer (GC) risk. However, the underlying biological mechanisms remain po...
Distinct Evolutionary Dynamics of HER2-Ultralow Versus HER2-Null from Residual to Metastatic Disease in Non-pCR Breast Cancer [0.03%]
HER2-超低水平与HER2-阴性乳腺癌非完全缓解患者残留病灶和转移性疾病中独特的进化动力学差异
Shunan Wang,Jingjing Liu,Tong Liu et al.
Shunan Wang et al.
Purpose: In breast cancer (BC) patients without pathological complete response (pCR) after neoadjuvant therapy, residual disease drives recurrence. The HER2 spectrum now includes HER2-low and HER2-ultralow. HER2-low tumor...
Concurrent Chemoradiotherapy with or without Induction Chemoimmunotherapy in Unresectable Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Study [0.03%]
不可切除食管鳞癌同期化学免疫诱导治疗或单纯同期放化疗的多中心真实世界研究
Biqi Chen,Peiying Cen,Qi Cheng et al.
Biqi Chen et al.
Purpose: This study aimed to compare the efficacy and safety of concurrent chemoradiotherapy (CCRT) with or without induction chemoimmunotherapy (CI) in unresectable esophageal squamous cell carcinoma (ESCC). ...
Is Adjuvant Chemotherapy Necessary for All Patients with pT3N0 Rectal Cancer after Upfront Surgery? A Multicenter Retrospective Study [0.03%]
所有一期手术后的pT3N0期直肠癌患者都需要辅助化疗吗？一项多中心回顾性研究
Kyong-Min Kang,Ho Yung Lee,Hong-Min Ahn et al.
Kyong-Min Kang et al.
Purpose: The role of adjuvant chemotherapy (ACT) in pathologic T3N0 (pT3N0) rectal cancer, which has a favorable prognosis, remains controversial because high-risk groups for recurrence are not well defined. This study in...
A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations [0.03%]
一项评价Pemigatinib联合白蛋白结合型紫杉醇治疗FGFs/FGFRs异常胃癌患者的 Ib/II期临床试验
Minkyu Jung,Soo Hyun Park,Hyoyoung Kim et al.
Minkyu Jung et al.
Purpose: Pemigatinib is a selective inhibitor of fibroblast growth factor receptors (FGFR) 1-3 with demonstrated activity in tumors harboring FGFR2 fusions or amplifications. This phase Ib/II trial assessed the efficacy a...